Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
mobile icon
Close
  • Menu
  • Setting

Signaling Pathways

Items 31-40 of 152

Page
per page
  1. TAK-715
    A8688 TAK-715
    Summary: p38 MAPK inhibitor
      ≥40 mg/mL
  2. PD 169316
    A8689 PD 169316
    Target: p38
    Summary: P38 MAPK inhibitor
      insoluble in EtOH; insoluble in H2O; ≥15.3 mg/mL
  3. RO4987655
    B3261 RO4987655
    Summary: MEK inhibitor
      insoluble in H2O; insoluble in EtOH; ≥56.6 mg/mL
  4. TCS JNK 5a
    B3275 TCS JNK 5a
    Target: JNK
    Summary: JNK2 and JNK3 inhibitor
      ≥16.6 mg/mL
  5. SB 203580 hydrochloride
    B1285 SB 203580 hydrochloride
    Target: p38
    Summary: Specific p38-MAPKs inhibitor
      insoluble in EtOH; insoluble in H2O; ≥20.7 mg/mL
  6. BI-D1870
    B2227 BI-D1870
     1 Citation
    Target: p90 S6K
    Summary: P90 RSK inhibitor,ATP-competitive and cell-permeable
      insoluble in H2O; ≥19.55 mg/mL
  7. GW5074
    B1405 GW5074
    Summary: C-Raf inhibitor,potent and selective
      insoluble in EtOH; insoluble in H2O; ≥21.9 mg/mL
  8. SB590885
    B1406 SB590885
     1 Citation
    Summary: Potent B-Raf inhibitor
      insoluble in H2O; insoluble in EtOH; ≥4.54 mg/mL
  9. CC-401
    B1260 CC-401
    Summary: JNK inhibitor,ATP-competitive
      ≥19.4 mg/mL
  10. TAK-733
    B1621 TAK-733
    Target: MEK
    Summary: MEK allosteric site inhibitor
      ≥25.2 mg/mL

Items 31-40 of 152

Page
per page